Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Extensive-stage Small Cell Lung Cancer
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
The purpose of this study is to determine if a combination of investigational agents is safe to give to people with small cell lung cancer (SCLC) after standard chemotherapy has been attempted.
- Trial name
- NCT03085849
- Testing
- Durvalumab, Tremelimumab, SGI-110
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Catherine Shu
Small-cell Lung Cancer, Residual Tumor
Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer.
- Conditions
- Small-cell Lung Cancer, Residual Tumor, Radiation
- Trial name
- NCT06514118
- Testing
- residual tumor irradiation
- Where
- 3 sites in China
- Volunteers
- 70 people
- Sponsor
- Qingdao Central Hospital
Extensive Stage Lung Small Cell Cancer
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination…
- Trial name
- PrE0510 (NCT07057791)
- Testing
- Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- PrECOG, LLC.
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Small-cell Lung Cancer
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg).
- Trial name
- PASSION (NCT03417895)
- Testing
- SHR-1210, Apatinib
- Where
- 2 sites in China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Small Cell Lung Cancer, Extensive Stage Lung Cancer
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small cell lung cancer, or SCLC, constitutes approximately 15% of the 170,000 new cases of lung cancer diagnosed annually in the United States.
- Conditions
- Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
- Trial name
- NCT00856830
- Testing
- Novel Drug Combination
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Extensive Stage-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites.
- Trial name
- NCT07895056
- Testing
- ABBV-706, Tarlatamab, Atezolizumab
- Volunteers
- 80 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06838208
- Testing
- Tislelizumab, Carboplatin /Cisplatin, Etoposide
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Anhui Provincial Cancer Hospital
Extensive Disease Small Cell Lung Cancer
A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
The integration of tarlatamab, a bispecific T-cell engager molecule targeting both DLL3 and CD3, into the treatment algorithm for SCLC will substantially improve the prognosis of patients.
- Trial name
- REPLAT (NCT07699237)
- Testing
- Tarlatamab, Carboplatin, Etoposid
- Volunteers
- 54 people
- Sponsor
- University of Cologne
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Small Cell Lung Carcinoma
Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer
The purpose of this study is to evaluate the efficacy of radiotherapy as part of the combined treatment approach for patients diagnosed with histopathologically confirmed small cell lung cancer (SCLC) in the advanced stage of…
- Trial name
- NCT06529081
- Testing
- Palliative Radiotherapy, Radical/Ablative Radiotherapy
- Where
- 2 sites in Poland
- Volunteers
- 165 people
- Sponsor
- Copernicus Memorial Hospital
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
Extensive-Stage Small Cell Lung Cancer
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
This is a single-arm, open-lable exploratory study of Lurbinectedin in combination with Serplulimab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy…
- Trial name
- NCT06497530
- Testing
- Serplulimab, Lurbinectedin, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Extensive Stage Small Cell Lung Cancer
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cancer.
- Trial name
- NCT00028028
- Testing
- temsirolimus, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Small-cell Lung Cancer, Small Cell Lung Carcinoma
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
- Trial name
- NCT03532880
- Testing
- Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.
- Trial name
- NCT04422210
- Testing
- Venetoclax, Atezolizumab, Carboplatin
- Where
- 5 sites in United States, Denmark and 2 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Small-cell Lung Cancer, Brain Metastases
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
This is a single arm, multicenter phase II trial for 60 patients with untreated extensive stage (ES) small cell lung cancer (SCLC) with asymptomatic brain metastases.
- Trial name
- NCT04610684
- Testing
- Carboplatin, Etoposide, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Jeffrey Clarke
Stage IV Small Cell Lung Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized…
- Trial name
- PINNACLE (NCT01859741)
- Testing
- OMP-59R5, Etoposide, Cisplatin or Carboplatin
- Where
- 35 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.